Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Rituximab biosimilar - mAbxience

Next Previous
Drug Profile

Rituximab biosimilar - mAbxience

Alternative Names: MB01; Novex; Rituxikal; RTXM-83; Vivaxxia

Latest Information Update: 29 May 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator mAbxience
  • Developer Innogene Kalbiotech; Libbs Farmaceutica; mAbxience
  • Class Anti-inflammatories; Antineoplastics; Antirheumatics; Eye disorder therapies; Immunotherapies; Monoclonal antibodies; Skin disorder therapies; Urologics; Vascular disorder therapies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Chronic lymphocytic leukaemia; Diffuse large B cell lymphoma; Follicular lymphoma; Non-Hodgkin's lymphoma

Most Recent Events

  • 28 Sep 2021 No development reported - Phase-III for Diffuse large B cell lymphoma (Combination therapy, First-line therapy) in Spain, Thailand, Philippines, Malaysia (IV)
  • 09 Dec 2017 Efficacy, safety and pharmacokinetics data from a phase III trial in Diffuse large B-cell lymphoma presented at the 59th Annual Meeting and Exposition of the American Society of Hematology (ASH-2017)
  • 01 May 2013 Phase-III clinical trials in Diffuse large B cell lymphoma (Combination therapy, First-line therapy) in Philippines (IV)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top